Julphar Bangladesh Launched- Daclacee (first time in Bangladesh)
To extend the horizon of Antiviral treatment Julphar Bangladesh has launched another breakthrough Antiviral product Daclacee (Daclatavir 60 mg) first time in Bangladesh.
- Provide Pangenotypic anti-HCV activity
- High SVR rate
- Less treatment duration and cost
- Convenient oral treatment regimen
Daclacee (Daclatasvir 60 mg) tablet can be taken orally once daily with Hepcee (Sofosbuvir 400 mg), if needed weight based Ribavirin (800 mg to 1200 mg/day) can be added. Treatment should be continued 12 or 24 weeks based on HCV genotype & disease stage.
Daclacee is the Antiviral drug for all genotypes and for all cases.